Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.

ABSTRACT: This article describes the population pharmacokinetics (PK) of dalteparin in pediatric patients with venous thromboembolism (VTE). A prospective multicenter open-label study was conducted in children who required anticoagulation for the treatment of VTE. The study population included children with and without cancer. The goal was to describe the pharmacokinetics of dalteparin using anti-Xa as a surrogate marker and to determine the dose required to achieve therapeutic anti-Xa levels (0.5-1.0 IU/mL). The anti-Xa data were supplemented with 2 published studies and analyzed using population pharmacokinetic approaches. The pharmacokinetics of dalteparin following subcutaneous injection in pediatric patients was described by a 1-compartment model with linear absorption and elimination. Body wei

SUBMITTER: Damle B 

PROVIDER: S-EPMC7818112 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature